Skip to content
Homepage
Author:
NurExone Biologic Inc
Posted Date:
July 30, 2026
NurExone Launches Bioprocess Optimization Initiative to Support Commercial and Clinical Readiness
NurExone Biologic Inc
July 30, 2026
Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors
NurExone Biologic Inc
July 28, 2026
NurExone Announces Closing of Non-Brokered Private Placement
NurExone Biologic Inc
June 30, 2026
Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico
NurExone Biologic Inc
June 24, 2026
